

Lucia Del Mastro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6963232/publications.pdf>

Version: 2024-02-01

333
papers

12,528
citations

30070

54
h-index

31849

101
g-index

339
all docs

339
docs citations

339
times ranked

11300
citing authors

#	ARTICLE	IF	CITATIONS
1	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492.	1.6	835
2	Survival and safety of exemestane versus tamoxifen after 2â€“3 years' tamoxifen treatment (Intergroup) Tj ETQq0 0.0,rgBT /Overlock 10	13.7	805
3	Cancer and fertility preservation: international recommendations from an expert meeting. <i>BMC Medicine</i> , 2016, 14, 1.	5.5	521
4	Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. <i>Supportive Care in Cancer</i> , 1999, 7, 121-127.	2.2	447
5	Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 994-1004.	1.2	393
6	Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 269-76.	7.4	311
7	Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2018, 29, 1497-1508.	1.2	305
8	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patientâ€“Level Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 1981-1990.	1.6	268
9	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€“298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	13.7	260
10	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. <i>Annals of Oncology</i> , 2021, 32, 1571-1581.	1.2	225
11	Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2851-2855.	1.6	218
12	Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. <i>Cancer Treatment Reviews</i> , 2018, 68, 102-110.	7.7	183
13	Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2632.	7.4	180
14	Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. <i>Annals of Oncology</i> , 2015, 26, 2408-2419.	1.2	178
15	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 675-683.	7.7	169
16	Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. <i>Cancer Treatment Reviews</i> , 2016, 49, 65-76.	7.7	167
17	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2â€“2 factorial, randomised phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1863-1872.	13.7	164
18	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 608.	2.8	160

#	ARTICLE	IF	CITATIONS
19	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology, The</i> , 2021, 22, 1139-1150.	10.7	147
20	Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 1996, 14, 3112-3120.	1.6	146
21	Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1724-1733.	6.3	146
22	Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1972-1979.	1.6	133
23	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology, The</i> , 2019, 20, 1360-1369.	10.7	131
24	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2018, 19, 249-256.	10.7	130
25	Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2715-2721.	1.6	118
26	Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. <i>Breast Cancer Research and Treatment</i> , 1997, 43, 183-190.	2.5	116
27	Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. <i>Lancet Oncology, The</i> , 2021, 22, e303-e313.	10.7	116
28	Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 5117-5125.	1.6	114
29	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. <i>Lancet Oncology, The</i> , 2022, 23, 382-392.	10.7	107
30	The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. <i>Annals of Oncology</i> , 2016, 27, 2224-2229.	1.2	103
31	Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. <i>British Journal of Cancer</i> , 1991, 63, 799-803.	6.4	101
32	Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. <i>Annals of Oncology</i> , 2006, 17, 74-78.	1.2	92
33	Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. <i>Cancer Research</i> , 2020, 80, GS3-04-GS3-04.	0.9	90
34	Sequential Treatment with Exemestane and Non-Steroidal Aromatase Inhibitors in Advanced Breast Cancer. <i>Oncology</i> , 2005, 69, 471-477.	1.9	88
35	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83.	7.7	88
36	The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 112-128.	4.4	87

#	ARTICLE	IF	CITATIONS
37	Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. <i>Cancer Treatment Reviews</i> , 2016, 46, 20-26.	7.7	87
38	Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. <i>Cancer Treatment Reviews</i> , 2019, 72, 65-77.	7.7	83
39	Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. <i>Annals of Oncology</i> , 2002, 13, 883-888.	1.2	82
40	Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. <i>European Journal of Cancer</i> , 2017, 71, 25-33.	2.8	79
41	The role of pneumatic compression in the treatment of postmastectomy lymphedema. A randomized phase III study. <i>Annals of Oncology</i> , 1998, 9, 187-190.	1.2	76
42	Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). <i>Annals of Oncology</i> , 2005, 16, 253-258.	1.2	76
43	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , 2018, 42, 41-49.	2.2	75
44	Gene expression profiling in breast cancer: A clinical perspective. <i>Breast</i> , 2013, 22, 109-120.	2.2	73
45	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	6.3	73
46	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 105-114.	1.6	72
47	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	1.6	70
48	Predicting mood disorders in breast cancer patients. <i>European Journal of Cancer</i> , 2001, 37, 216-223.	2.8	69
49	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	1.6	69
50	Fertility and pregnancy issues in <i>BRCA</i> -mutated breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017, 59, 61-70.	7.7	68
51	Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 1999, 17, 1132-1132.	1.6	65
52	Tamoxifen and the endometrium: findings of pelvic ultrasound examination. <i>Breast Cancer Research and Treatment</i> , 1998, 47, 41-46.	2.5	64
53	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
54	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	6.3	59

#	ARTICLE	IF	CITATIONS
55	Treatment of breast cancer during pregnancy: Regimen selection, pregnancy monitoring and more. <i>Breast</i> , 2011, 20, 1-6.	2.2	57
56	Angiosarcoma of the residual breast after conservative surgery and radiotherapy for primary carcinoma. <i>Annals of Oncology</i> , 1994, 5, 163-165.	1.2	53
57	Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epirubicin, and fluorouracil in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 1996, 14, 764-773.	1.6	53
58	Increases in Tumor N-glycan Polylactosamines Associated with Advanced HER2-Positive and Triple-Negative Breast Cancer Tissues. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800014.	1.6	50
59	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2018, 3, e000361.	4.5	49
60	Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 574669.	2.8	48
61	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103365.	4.4	48
62	State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. <i>Cancer Treatment Reviews</i> , 2017, 57, 50-57.	7.7	47
63	Infertility and pregnancy after breast cancer: Current knowledge and future perspectives. <i>Cancer Treatment Reviews</i> , 2006, 32, 417-422.	7.7	46
64	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1471-1478.	6.4	45
65	Sequence Effect of Epirubicin and Paclitaxel Treatment on Pharmacokinetics and Toxicity. <i>Journal of Clinical Oncology</i> , 2000, 18, 2116-2125.	1.6	44
66	Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes. <i>European Journal of Surgical Oncology</i> , 2011, 37, 688-694.	1.0	44
67	Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ovest/Mammella Inter Gruppo Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2213-2221.	1.6	41
68	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. <i>Breast</i> , 2018, 41, 51-56.	2.2	41
69	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	10.7	41
70	Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. <i>Human Reproduction</i> , 2022, 37, 954-968.	0.9	41
71	Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. <i>Journal of Translational Medicine</i> , 2015, 13, 324.	4.4	40
72	New emerging targets in cancer immunotherapy: the role of GITR. <i>ESMO Open</i> , 2019, 4, e000738.	4.5	40

#	ARTICLE	IF	CITATIONS
73	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	2.8	39
74	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 118, 178-186.	2.8	39
75	Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1049-1049.	1.6	39
76	Temporary Ovarian Suppression With Gonadotropinâ€Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?. <i>Oncologist</i> , 2015, 20, 1233-1235.	3.7	38
77	Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. <i>JCO Oncology Practice</i> , 2020, 16, e1304-e1314.	2.9	38
78	Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. <i>European Journal of Cancer</i> , 2002, 38, 359-366.	2.8	37
79	HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. <i>British Journal of Cancer</i> , 2005, 93, 7-14.	6.4	37
80	Update on the Management of Breast Cancer during Pregnancy. <i>Cancers</i> , 2020, 12, 3616.	3.7	37
81	Follow-up of patients with early breast cancer: Is it time to rewrite the story?. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 130-141.	4.4	36
82	Medical approaches to preservation of fertility in female cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 387-396.	1.8	35
83	Anti-MÃ¼llerian hormone: determination of ovarian reserve in early breast cancer patients. <i>Endocrine-Related Cancer</i> , 2014, 21, R51-R65.	3.1	35
84	Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 45-53.	2.5	33
85	A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. <i>Breast</i> , 2010, 19, 333-338.	2.2	33
86	Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptorâ€Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1258-1267.	1.6	33
87	Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases. <i>Breast Care</i> , 2020, 15, 148-156.	1.4	32
88	Call for ensuring cancer care continuity during COVID-19 pandemic. <i>ESMO Open</i> , 2020, 5, e000783.	4.5	31
89	Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patientsâ€With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. <i>Clinical Breast Cancer</i> , 2017, 17, 601-610.e2.	2.4	30
90	The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 346.	2.6	30

#	ARTICLE	IF	CITATIONS
91	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e181-e187.	2.4	30
92	Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1237-1242.	1.2	29
93	Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 37, 142-147.	2.2	29
94	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019, 38, 835-844.	2.4	29
95	Randomized cooperative study of perioperative chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2712-2721.	1.6	28
96	Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases. <i>Annals of Oncology</i> , 2014, 25, 912-913.	1.2	28
97	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients. <i>Annals of Oncology</i> , 2015, 26, vi1.	1.2	28
98	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13315.	3.4	28
99	Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1529-1539.	6.3	27
100	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. <i>Oncologist</i> , 2015, 20, 880-889.	3.7	26
101	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	4.5	26
102	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254.	7.4	25
103	Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 269-275.	2.5	24
104	Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 133-139.	2.5	23
105	Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. <i>Cancer</i> , 2003, 97, 1174-1180.	4.1	23
106	The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 690320.	2.8	23
107	Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. <i>Annals of Oncology</i> , 2001, 12, 1097-1106.	1.2	22
108	Long-Term Follow-Up of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2507-2514.	1.6	22

#	ARTICLE	IF	CITATIONS
109	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq1 1 0.784314 14 29 BT /Over 1137.	3.7	29
110	Chemotherapy of non-small-cell lung cancer: Role of erythropoietin in the management of anemia. <i>Annals of Oncology</i> , 1999, 10, S91-S94.	1.2	21
111	Role of colony stimulating factors (CSFs) in solid tumours: Results of an expert panel. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 53-64.	4.4	21
112	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. <i>Cancers</i> , 2022, 14, 2136.	3.7	21
113	Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 804-805.	1.6	20
114	Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. <i>Clinical Medicine Insights Reproductive Health</i> , 2019, 13, 117955811986458.	3.9	20
115	Fertility, sexuality and cancer in young adult women. <i>Current Opinion in Oncology</i> , 2019, 31, 259-267.	2.4	20
116	Definition of High-Risk Early Hormone-Positive HER2~Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
117	Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy. <i>Cancer</i> , 1994, 74, 2300-2306.	4.1	19
118	Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1391-1405.	2.4	19
119	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. <i>BMC Cancer</i> , 2013, 13, 164.	2.6	19
120	Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 167-174.	2.5	19
121	Protecting Ovaries During Chemotherapy Through Gonad Suppression. <i>Obstetrics and Gynecology</i> , 2015, 126, 901.	2.4	19
122	A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. <i>European Journal of Cancer</i> , 1994, 30, 606-610.	2.8	18
123	Maintenance Hormone Therapy with Letrozole after First-Line Chemotherapy for Advanced Breast Cancer. <i>Oncology</i> , 2005, 68, 364-370.	1.9	18
124	Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest~Mammella Intergruppo (GONO-MIG) Group. <i>Annals of Oncology</i> , 2008, 19, 299-307.	1.2	18
125	Exploring the safety of chemotherapy for treating breast cancer during pregnancy. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1395-1408.	2.4	18
126	Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers ~ESEMPiO study. <i>Future Oncology</i> , 2019, 15, 33-44.	2.4	18

#	ARTICLE	IF	CITATIONS
127	Abstract GS1-01: Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials. <i>Cancer Research</i> , 2018, 78, GS1-01-GS1-01.	0.9	18
128	Safety of adjuvant aromatase inhibitor therapy. <i>Cancer Treatment Reviews</i> , 2006, 32, 548-556.	7.7	17
129	A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes. <i>European Journal of Surgical Oncology</i> , 2014, 40, 835-842.	1.0	17
130	Pegfilgrastim administration after 24 or 72 or 96h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. <i>Supportive Care in Cancer</i> , 2016, 24, 1285-1294.	2.2	17
131	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 4.	3.0	17
132	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	3.7	17
133	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	5.2	17
134	Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer. <i>Annals of Oncology</i> , 2002, 13, 280-285.	1.2	16
135	Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. <i>Annals of Oncology</i> , 2002, 13, 546-552.	1.2	16
136	Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. <i>Annals of Oncology</i> , 2003, 14, 1222-1226.	1.2	16
137	Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1799-1817.	3.1	16
138	Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. <i>Breast</i> , 2017, 33, 104-108.	2.2	16
139	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 62, 123-132.	7.7	16
140	Fertility counseling of young breast cancer patients. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 1, S68-80.	1.4	16
141	Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate. <i>Annals of Oncology</i> , 2022, 33, 347-349.	1.2	16
142	Circulating miRNAs in Breast Cancer Diagnosis and Prognosis. <i>Cancers</i> , 2022, 14, 2317.	3.7	16
143	Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives. <i>Cancer Treatment Reviews</i> , 2011, 37, 208-211.	7.7	15
144	Management of young women with early breast cancer. <i>ESMO Open</i> , 2018, 3, e000458.	4.5	15

#	ARTICLE	IF	CITATIONS
145	Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6045.	4.1	15
146	Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. <i>Breast</i> , 2020, 52, 23-32.	2.2	15
147	Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 400-408.	6.3	15
148	Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 4557-4561.	3.7	14
149	Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. <i>Annals of Oncology</i> , 2001, 12, 505-508.	1.2	13
150	Sentinel lymph node biopsy in breast cancer patients: The medical oncology perspective. <i>Journal of Surgical Oncology</i> , 2004, 85, 129-132.	1.7	13
151	Estrone Sulphate, FSH, and Testosterone Levels in Two Male Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Oncologist</i> , 2010, 15, 1270-1272.	3.7	13
152	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. <i>Breast</i> , 2013, 22, 470-475.	2.2	13
153	Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 47-59.	0.6	13
154	Efficacy and safety of eribulin in taxane-refractory patients in the "real world". <i>Future Oncology</i> , 2017, 13, 971-978.	2.4	13
155	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	5.2	13
156	Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group.. <i>Journal of Clinical Oncology</i> , 2010, 28, 528-528.	1.6	13
157	Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and Î²2-microglobulin downregulation in breast cancer. <i>Human Immunology</i> , 2009, 70, 492-495.	2.4	12
158	5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 117-126.	2.5	12
159	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	5.1	12
160	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020, 122, 1611-1617.	6.4	12
161	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. <i>ESMO Open</i> , 2021, 6, 100099.	4.5	12
162	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12

#	ARTICLE	IF	CITATIONS
163	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. <i>BMJ Open</i> , 2021, 11, e049128.	1.9	12
164	Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 1990, 16, 111-117.	2.5	11
165	Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 487-494.	2.3	11
166	Reducing the risk of distant metastases in breast cancer patients: Role of aromatase inhibitors. <i>Cancer Treatment Reviews</i> , 2007, 33, 681-687.	7.7	11
167	Stevens-Johnson syndrome after treatment with bendamustine. <i>Leukemia Research</i> , 2012, 36, e153-e154.	0.8	11
168	Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 211-218.	2.4	11
169	New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. <i>Cancer Treatment Reviews</i> , 2016, 42, 18-23.	7.7	11
170	Taxane-containing chemotherapy in the treatment of early breast cancer patients. <i>Annals of Oncology</i> , 2006, 17, vii22-vii26.	1.2	10
171	Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2566-2567.	1.6	10
172	Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1303-1313.	2.4	10
173	Trastuzumab emtansine in the treatment of <i>HER-2</i> -positive metastatic breast cancer patients. <i>Future Oncology</i> , 2013, 9, 955-957.	2.4	10
174	Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. <i>British Journal of Cancer</i> , 2014, 110, 1133-1138.	6.4	10
175	Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle?. <i>Annals of Oncology</i> , 2017, 28, 1683-1685.	1.2	10
176	Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). <i>European Journal of Cancer</i> , 2018, 99, 9-19.	2.8	10
177	Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 504-504.	1.6	10
178	Thymidine Labeling Index Analysis in Early Breast Cancer Patients Randomized to Receive Perioperative Chemotherapy. <i>Oncology</i> , 2001, 60, 88-93.	1.9	9
179	Fertility Preservation Strategies for Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 4220-4221.	1.6	9
180	Hexaprimer Amplification Refractory Mutation System PCR for Simultaneous Single-Tube Genotyping of 2 Close Polymorphisms. <i>Clinical Chemistry</i> , 2008, 54, 227-229.	3.2	9

#	ARTICLE	IF	CITATIONS
181	Pharmacotherapy to protect ovarian function and fertility during cancer treatment. Expert Opinion on Pharmacotherapy, 2017, 18, 739-742.	1.8	9
182	Body weight and return to work among survivors of early-stage breast cancer. ESMO Open, 2020, 5, e000908.	4.5	9
183	Multigene tests for breast cancer: the physician's perspective. Oncotarget, 2021, 12, 936-947.	1.8	9
184	Mitomycin C and Mitoxantrone in Anthracycline-Pretreated Advanced Breast Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 218-222.	1.3	8
185	ATAC trial update. Lancet, The, 2005, 365, 1225.	13.7	8
186	Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study. Annals of Oncology, 2010, 21, 2029-2039.	1.2	8
187	Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. Expert Review of Clinical Pharmacology, 2016, 9, 1153-1161.	3.1	8
188	Reply to the letter to the editor "Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?" by Rodriguez-Wallberg et al.. Annals of Oncology, 2016, 27, 548-549.	1.2	8
189	News on the medical treatment of young women with early-stage HER2-negative breast cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1643-1655.	1.8	8
190	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients.. Journal of Clinical Oncology, 2014, 32, 105-105.	1.6	8
191	Treatment with aromatase inhibitors and markers of cardiovascular disease. Breast Cancer Research and Treatment, 2016, 160, 261-267.	2.5	7
192	Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open, 2021, 6, 100054.	4.5	7
193	COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?. ESMO Open, 2021, 6, 100100.	4.5	7
194	Abstract S5-06: Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study. , 2013, , ,		7
195	Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery. Annals of Oncology, 2001, 12, 373-378.	1.2	6
196	Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer, 2012, 12, 216.	2.6	6
197	Pharmacokinetics of Trastuzumab in Haemodialysis. Breast Journal, 2015, 21, 329-331.	1.0	6
198	Fertility preservation inBRCA-mutated breast cancer patients. Breast Cancer Management, 2016, 5, 61-68.	0.2	6

#	ARTICLE	IF	CITATIONS
199	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018, 18, 932.	2.6	6
200	Reply to V. Turan et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 86-88.	1.6	6
201	Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. <i>Breast Journal</i> , 2019, 25, 444-449.	1.0	6
202	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	2.8	6
203	Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 241-250.	2.4	6
204	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	5.2	6
205	Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: Final results from the Italian MANTA study. <i>Journal of Clinical Oncology</i> , 2005, 23, 522-522.	1.6	6
206	Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 516-516.	1.6	6
207	De novo metastatic breast cancer arising in young women: review of the current evidence. <i>Clinical Breast Cancer</i> , 2021, , .	2.4	6
208	Weekly Paclitaxel in Elderly Patients with Advanced Breast Cancer. <i>Drugs in R and D</i> , 2004, 5, 11-15.	2.2	5
209	Progesterone Receptor Status and Clinical Outcome in Breast Cancer Patients with Estrogen Receptor-Positive Locoregional Recurrence. <i>Tumori</i> , 2015, 101, 398-403.	1.1	5
210	Luteinizing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1357-1362.	1.8	5
211	Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence. <i>Blood Purification</i> , 2018, 46, 56-69.	1.8	5
212	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	2.4	5
213	Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. <i>ESMO Open</i> , 2020, 5, e000719.	4.5	5
214	Diversity of Cardiologic Issues in a Contemporary Cohort of Women With Breast Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 654728.	2.4	5
215	Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046). , 2020, , .		5
216	Strategies for the Use of Epoetin Alfa in Breast Cancer Patients. <i>Oncologist</i> , 1998, 3, 314-318.	3.7	5

#	ARTICLE	IF	CITATIONS
217	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	3.2	5
218	Temporary Ovarian Suppression With Goserelin and Ovarian Function Protection in Patients With Breast Cancer Undergoing Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 3339-3340.	1.6	4
219	Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology. <i>Tumori</i> , 2016, 102, 108-113.	1.1	4
220	A survey on physicians' knowledge, practice and attitudes on fertility and pregnancy issues in young breast cancer patients. <i>Breast</i> , 2017, 32, S85-S86.	2.2	4
221	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. <i>Oncotarget</i> , 2017, 8, 44800-44810.	1.8	4
222	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018, 40, 45-52.	2.2	4
223	Role of dose-dense chemotherapy in high-risk early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 480-485.	2.4	4
224	Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4364.	4.1	4
225	Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	1.3	4
226	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	7.0	4
227	Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study. <i>Cancer Research</i> , 2017, 77, P4-21-39-P4-21-39.	0.9	4
228	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 527-527.	1.6	4
229	Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6320.	4.1	4
230	Adjuvant Chemotherapy in Breast Cancer. <i>New England Journal of Medicine</i> , 1995, 333, 596-597.	27.0	3
231	More on dose-intensity of anthracyclines in breast cancer. <i>Annals of Oncology</i> , 1998, 9, 461.	1.2	3
232	Le Linee Guida Aiom per le Neoplasie Della Mammella. <i>Tumori</i> , 2004, 90, 1-8.	1.1	3
233	Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1050-1051.	6.3	3
234	Gonadotropin-Releasing Hormone Analogue for Premenopausal Women With Breast Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1760.	7.4	3

#	ARTICLE	IF	CITATIONS
235	Letrozole withdrawal response in locally advanced breast cancer. <i>Annals of Oncology</i> , 2011, 22, 1927-1928.	1.2	3
236	Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?. <i>European Journal of Cancer</i> , 2016, 54, 163-164.	2.8	3
237	First Surgical National Consensus Conference of the Italian Breast Surgeons association (ANISC) on breast cancer management in neoadjuvant setting: Results and summary. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1913-1919.	1.0	3
238	HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy (CT) in early breast cancer (BC) patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 571-571.	1.6	3
239	Erlotinib given sequentially to capecitabine and vinorelbine as first-second line chemotherapy in metastatic breast cancer patients. A dose finding study. <i>Journal of Clinical Oncology</i> , 2004, 22, 834-834.	1.6	3
240	Temporary ovarian suppression with goserelin for prevention of chemotherapy-induced menopause in young early breast cancer patients: Results of a phase II study. <i>Journal of Clinical Oncology</i> , 2005, 23, 662-662.	1.6	3
241	A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPIo study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11539-e11539.	1.6	3
242	Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 515-515.	1.6	3
243	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients. <i>Minerva Obstetrics and Gynecology</i> , 2017, 69, 350-356.	1.0	3
244	Plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment: Association with single nucleotide polymorphisms (SNPs) of CYP19A1. <i>Journal of Clinical Oncology</i> , 2009, 27, 555-555.	1.6	3
245	Fertility issues in young breast cancer patients: what women want. <i>Journal of Thoracic Disease</i> , 2014, 6, 584-8.	1.4	3
246	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1117-1126.	6.3	3
247	Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. <i>ESMO Open</i> , 2022, 7, 100483.	4.5	3
248	Endocrine Factors in the Outcome of Systemic Adjuvant Therapy of Early Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 330-338.	3.8	2
249	Is it Possible to use Anthracyclines in Patients Older than 70 Years? <i>Contra. Tumori</i> , 2002, 88, S136-S137.	1.1	2
250	Use in current clinical practice of 70-gene signature in early breast cancer. <i>International Journal of Cancer</i> , 2010, 127, 2736-2737.	5.1	2
251	Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1137-1138.	1.6	2
252	Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. <i>ESMO Open</i> , 2020, 5, e000979.	4.5	2

#	ARTICLE	IF	CITATIONS
253	Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC). <i>Journal of Clinical Oncology</i> , 2008, 26, 1034-1034.	1.6	2
254	Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12507-e12507.	1.6	2
255	High Dose Intensity Chemotherapy without Bone Marrow Support: Role of Granulocyte-Macrophage Colony-Stimulating Factor. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 389-397.	3.8	1
256	Reply to "Weekly paclitaxel in elderly breast cancer patients", by C. Smorenburg et al. (<i>Ann Oncol</i> 2005;) <i>TJ ET O g 0 0 0 rg BT / Overlo</i>	1.2	1
257	The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients. <i>Annals of Oncology</i> , 2008, 19, 1213-1215.	1.2	1
258	Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?. <i>Annals of Oncology</i> , 2010, 21, 1376-1377.	1.2	1
259	HM35 Role of temporary ovarian suppression obtained with GnRH analogue in reducing premature ovarian failure induced by chemotherapy in premenopausal cancer patients: a meta-analysis of randomized studies. <i>Breast</i> , 2012, 21, S13.	2.2	1
260	Pertuzumab and Trastuzumab in Combination with Vinorelbine for First-Line Treatment of Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (LABC/MBC): A Single-Arm, Two-Cohort, Phase II Study (Velvet). <i>Annals of Oncology</i> , 2012, 23, ix142.	1.2	1
261	Anthracycline-free therapy for HER2 -amplified breast cancer. <i>Lancet Oncology, The</i> , 2013, 14, 1037-1038.	10.7	1
262	1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies. <i>European Journal of Cancer</i> , 2015, 51, S318-S319.	2.8	1
263	The value of hormone serum concentration to predict the gonadotoxic effect of chemotherapy and the efficacy of LHRH analogs as a strategy to reduce treatment-related premature ovarian failure in breast cancer. <i>Annals of Oncology</i> , 2015, 26, vi8.	1.2	1
264	Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. <i>Future Oncology</i> , 2015, 11, 2251-2254.	2.4	1
265	Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study. <i>Annals of Oncology</i> , 2017, 28, v83-v84.	1.2	1
266	The BCY3/BCC 2017 survey on physicians'™ knowledge, attitudes and practice towards fertility and pregnancy issues in young breast cancer patients. <i>European Journal of Cancer</i> , 2018, 92, S22.	2.8	1
267	The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial. <i>Annals of Oncology</i> , 2019, 30, iii28.	1.2	1
268	Dose-dense adjuvant chemotherapy in early breast cancer: 15-year results of the phase III Mammella InterGruppo (MIG)-1 study. <i>Annals of Oncology</i> , 2019, 30, iii27.	1.2	1
269	Reply to the letter "Safety of fertility preservation in women with breast cancer", <i>Breast</i> , 2019, 43, 149-150.	2.2	1
270	11P BioltaLEE: Comparative biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC). <i>Annals of Oncology</i> , 2020, 31, S20.	1.2	1

#	ARTICLE	IF	CITATIONS
271	Putting the Taxanes to Work: Unanswered Questions. Recent Results in Cancer Research, 1998, 152, 305-313.	1.8	1
272	Once-weekly epoetin beta treatment in anemic patients with breast cancer receiving chemotherapy: Interim analysis of a multicenter, single arm study. Journal of Clinical Oncology, 2007, 25, 19605-19605.	1.6	1
273	Single-nucleotide polymorphisms (SNPs) of CYP19A1 and plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.. Journal of Clinical Oncology, 2010, 28, 2606-2606.	1.6	1
274	Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.. Journal of Clinical Oncology, 2011, 29, 515-515.	1.6	1
275	PARP inhibitors (PARPi) for the treatment of <i>BRCA</i> -mutated HER2-negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2018, 36, e13098-e13098.	1.6	1
276	Anti-Mullerian hormone (AMH) and ovarian function in young breast cancer (BC) women receiving adjuvant chemotherapy (CT). Journal of Clinical Oncology, 2009, 27, e11544-e11544.	1.6	1
277	Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 1057-1057.	1.6	1
278	The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.. Journal of Clinical Oncology, 2017, 35, 1055-1055.	1.6	1
279	Platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): A systematic review and meta-analysis of randomized controlled trials (RCTs).. Journal of Clinical Oncology, 2018, 36, 595-595.	1.6	1
280	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. Tumori, 2022, , 030089162110675.	1.1	1
281	Paradoxical Effect of Cytotoxic Chemotherapy on Anemia in Cancer Patients With \hat{A} -Thalassemia Minor. Journal of the National Cancer Institute, 1997, 89, 455-456.	6.3	0
282	S29 Putting the taxanes to work: Open questions. European Journal of Cancer, 1998, 34, S7.	2.8	0
283	P29 Tumor proliferative activity evaluated with thymidine labelling index predicts response to adjuvant chemotherapy. European Journal of Cancer, 1998, 34, S21.	2.8	0
284	Dose-dense sequential administration and same day administration of epirubicin and paclitaxel yield similar response rates in women with advanced breast cancer. Evidence-based Oncology, 2001, 2, 211-213.	0.1	0
285	Reply to A. SÃ¡nchez-MuÃ±oz et al. Journal of Clinical Oncology, 2009, 27, e257-e258.	1.6	0
286	Role of Temporary Ovarian Suppression Obtained with GNRH Analog in Reducing Premature Ovarian Failure (POF) Induced By Chemotherapy in Premenopausal Cancer Patients: a Meta-Analysis of Randomized Studies. Annals of Oncology, 2012, 23, ix501.	1.2	0
287	Fertility Preservation in Young Early Breast Cancer: Strategies and Patient Preferences. Annals of Oncology, 2012, 23, ix521.	1.2	0
288	Incidence of Hepatitis B and C Infections in Early Breast Cancer Patients and Impact on Systemic Treatments. Annals of Oncology, 2012, 23, ix454.	1.2	0

#	ARTICLE	IF	CITATIONS
289	Doseâ€Dense FEC Followed by Doseâ€Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study. <i>Oncologist</i> , 2013, 18, 924-925.	3.7	0
290	Doseâ€Dense FEC Followed by Doseâ€Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study. <i>Oncologist</i> , 2013, 18, 1149-1149.	3.7	0
291	OR30 Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (pregnancy and fertility) trial. <i>Breast</i> , 2014, 23, S12.	2.2	0
292	1849 Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPiO study. <i>European Journal of Cancer</i> , 2015, 51, S281-S282.	2.8	0
293	1863 First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab. <i>European Journal of Cancer</i> , 2015, 51, S286.	2.8	0
294	PO62 FIRST LINE TRASTUZUMAB-BASED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PRESENTING WITH DE NOVO OR RECURRENT DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY. <i>Breast</i> , 2015, 24, S43.	2.2	0
295	Correlation between treatment with aromatase inhibitors and carotid intima-media thickness, carotid stenosis and abdominal aortic diameter. A prospective cohort study. <i>Annals of Oncology</i> , 2015, 26, vi10.	1.2	0
296	First line trastuzumab-based therapy in her2-positive metastatic breast cancer patients presenting with de novo or recurrent disease. <i>Annals of Oncology</i> , 2015, 26, vi10.	1.2	0
297	1861 Body mass index and prognosis in HER2-positive metastatic breast cancer patients. <i>European Journal of Cancer</i> , 2015, 51, S285-S286.	2.8	0
298	A meta-analysis on impact of age at first pregnancy on the risk of developing breast cancer according to subtype. <i>Annals of Oncology</i> , 2015, 26, vi5.	1.2	0
299	Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: a systematic review and meta-analysis of randomized studies. <i>Annals of Oncology</i> , 2015, 26, vi2.	1.2	0
300	Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (PREgnancy and FERtility) trial. <i>Annals of Oncology</i> , 2015, 26, vi10.	1.2	0
301	Outcomes of hormone-responsive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC) patients (P) according to their starting first-line (1st) treatment (T): chemotherapy (CT) or hormonal therapy (HT). <i>Annals of Oncology</i> , 2015, 26, vi11.	1.2	0
302	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: an international multicentre hospital-based retrospective cohort study. <i>Annals of Oncology</i> , 2016, 27, vi49.	1.2	0
303	Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study. <i>Annals of Oncology</i> , 2016, 27, iv70.	1.2	0
304	The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy. <i>Annals of Oncology</i> , 2016, 27, iv64.	1.2	0
305	The effect of financial difficulties on clinical outcomes in Italian cancer patients: a pooled analysis of 16 academic prospective clinical trials. <i>Annals of Oncology</i> , 2016, 27, iv111.	1.2	0
306	health economics The effect of financial difficulties on clinical outcomes in Italian cancer patients: A pooled analysis of 16 academic prospective clinical trials. <i>Annals of Oncology</i> , 2016, 27, vi572.	1.2	0

#	ARTICLE	IF	CITATIONS
307	TP53 germline mutation testing in early onset breast cancer. <i>Annals of Oncology</i> , 2016, 27, iv71.	1.2	0
308	Adverse Events (AE) of Targeted Agents Added to Endocrine Therapy in Patients with Hormone Receptor-positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. <i>Breast</i> , 2017, 36, S43-S44.	2.2	0
309	A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice. <i>JAMA Oncology</i> , 2017, 3, 735.	7.1	0
310	NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study. <i>Breast</i> , 2017, 36, S51-S52.	2.2	0
311	A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer. <i>Annals of Oncology</i> , 2017, 28, vi25.	1.2	0
312	The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts). <i>Annals of Oncology</i> , 2017, 28, vi26.	1.2	0
313	Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study. <i>Annals of Oncology</i> , 2018, 29, viii620-viii621.	1.2	0
314	Physicians'™ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey. <i>Annals of Oncology</i> , 2018, 29, viii606.	1.2	0
315	Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC). <i>Annals of Oncology</i> , 2018, 29, viii621.	1.2	0
316	Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial. <i>Annals of Oncology</i> , 2019, 30, v61.	1.2	0
317	Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study. <i>Annals of Oncology</i> , 2019, 30, v113.	1.2	0
318	T-DM1 EFFICACY AND ACTIVITY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PROGRESSING AFTER FRONTLINE TAXANE PLUS PERTUZUMAB AND TRASTUZUMAB: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY OF THE GRUPPO ITALIANO MAMMELLA (GIM) STUDY GROUP. <i>Breast</i> , 2019, 48, S45.	2.2	0
319	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	1.4	0
320	95TiP Gruppo Italiano Mammella (GIM) 10 - CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC). <i>Annals of Oncology</i> , 2020, 31, S47.	1.2	0
321	Abstract P1-11-20: Open-Label Phase II Study of Neoadjuvant Bevacizumab Combined with FEC+Paclitaxel in Patients with Inflammatory or Locally Advanced Breast Cancer. , 2010, , .		0
322	Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer. , 2013, , .		0
323	Pegfilgrastim (P) administration after 24, 72, or 96 hours (h) to allow dose-dense (DD) anthracycline- and taxane-based chemotherapy (CT) in breast cancer (BC) patients (pts): A single-center experience within the GIM2 randomized phase III study. <i>Journal of Clinical Oncology</i> , 2014, 32, 9632-9632.	1.6	0
324	First line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients (MBC) presenting with de novo or recurrent disease.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11575-e11575.	1.6	0

#	ARTICLE	IF	CITATIONS
325	Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials.. Journal of Clinical Oncology, 2016, 34, 529-529.	1.6	0
326	Abstract P5-15-07: First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13" "AMBRA" Italian study. , 2017, , .		0
327	Abstract P1-09-12: Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit. , 2017, , .		0
328	Trastuzumab-related cardiotoxicity in patients with non-limiting cardiac comorbidity.. Journal of Clinical Oncology, 2017, 35, e12043-e12043.	1.6	0
329	First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study.. Journal of Clinical Oncology, 2018, 36, e13032-e13032.	1.6	0
330	Abstract P6-21-13: A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2) "negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxel. , 2019, , .		0
331	Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.. Journal of Clinical Oncology, 2019, 37, e12528-e12528.	1.6	0
332	Abstract P4-14-01: Modulation of tumor infiltrating lymphocytes (TILs) by palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ patients (pts) enrolled in the Michelangelo NA-PHER2 trial. , 2020, , .		0
333	Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. JCO Precision Oncology, 2022, 6, e2100198.	3.0	0